Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBITDA (2016 - 2025)

Historic EBITDA for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.

  • CytomX Therapeutics' EBITDA fell 34494.81% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 10155.03%. This contributed to the annual value of $31.8 million for FY2024, which is 667045.45% up from last year.
  • CytomX Therapeutics' EBITDA amounted to -$14.2 million in Q3 2025, which was down 34494.81% from -$120000.0 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' EBITDA registered a high of $23.5 million during Q1 2025, and its lowest value of -$35.1 million during Q4 2021.
  • For the 5-year period, CytomX Therapeutics' EBITDA averaged around -$9.2 million, with its median value being -$6.5 million (2024).
  • Within the past 5 years, the most significant YoY rise in CytomX Therapeutics' EBITDA was 179577.89% (2024), while the steepest drop was 50556.59% (2024).
  • Quarter analysis of 5 years shows CytomX Therapeutics' EBITDA stood at -$35.1 million in 2021, then soared by 77.3% to -$8.0 million in 2022, then skyrocketed by 112.48% to $995000.0 in 2023, then surged by 1795.78% to $18.9 million in 2024, then crashed by 175.06% to -$14.2 million in 2025.
  • Its EBITDA stands at -$14.2 million for Q3 2025, versus -$120000.0 for Q2 2025 and $23.5 million for Q1 2025.